Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study
- Author:
Kazuya KARIYAMA
1
;
Kazuhiro NOUSO
;
Atsushi HIRAOKA
;
Hidenori TOYODA
;
Toshifumi TADA
;
Kunihiko TSUJI
;
Toru ISHIKAWA
;
Takeshi HATANAKA
;
Ei ITOBAYASHI
;
Koichi TAKAGUCHI
;
Akemi TSUTSUI
;
Atsushi NAGANUMA
;
Satoshi YASUDA
;
Satoru KAKIZAKI
;
Akiko WAKUTA
;
Shohei SHIOTA
;
Masatoshi KUDO
;
Takashi KUMADA
Author Information
- Publication Type:Original Article
- From:Journal of Liver Cancer 2024;24(1):71-80
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Background:/Aim: The aim of this study was to compare the therapeutic efficacy of ablation and surgery in solitary hepatocellular carcinoma (HCC) measuring ≤5 cm with a large HCC cohort database.
Methods:The study included consecutive 2,067 patients with solitary HCC who were treated with either ablation (n=1,248) or surgery (n=819). Th e patients were divided into three groups based on the tumor size and compared the outcomes of the two therapies using propensity score matching.
Results:No significant difference in recurrence-free survival (RFS) or overall survival (OS) was found between surgery and ablation groups for tumors measuring ≤2 cm or >2 cm but ≤3 cm. For tumors measuring >3 cm but ≤5 cm, RFS was significantly better with surgery than with ablation (3.6 and 2.0 years, respectively, P=0.0297). However, no significant difference in OS was found between surgery and ablation in this group (6.7 and 6.0 years, respectively, P=0.668).
Conclusion:The study suggests that surgery and ablation can be equally used as a treatment for solitary HCC no more than 3 cm in diameter. For HCCs measuring 3-5 cm, the OS was not different between therapies; thus, ablation and less invasive therapy can be considered a treatment option; however, special caution should be taken to prevent recurrence.
